RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
stockNASDAQ
recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.84 | 2026-10-13 | -5.61% | 11.748 |
| 1M | 3.97 | 2026-09-21 | -8.82% | 8.303 |
| 3M | 2.89 | 2026-07-20 | +25.26% | 3.902 |
| 6M | 3.69 | 2026-04-20 | -1.90% | 3.390 |
| 1Y | 6.68 | 2025-10-20 | -45.81% | 2.913 |
| 2Y | 6.76 | 2024-10-21 | -46.45% | — |
| 5Y | 18.45 | 2021-10-20 | -80.38% | 2.393 |
Recursion Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:RXRX) stock price today is $3.62, and today's volume is 12,871,981. RXRX is up 0.277% today. The 30 day average volume is 28.04M. RXRX market cap is $1.94B with 536.27M shares outstanding.